Can Tumor-Infiltrating Lymphocytes (TILs) Be a Predictive Factor for Lymph Nodes Status in Both Early Stage and Locally Advanced Breast Cancer?

Overview

Journal J Clin Med

Specialty General Medicine

Date 2019 Apr 25

PMID 31013579

Citations 5

Authors

Alexandra Caziuc

Diana Schlanger

Giorgiana Amarinei

George Calin Dindelegan

Affiliations

Soon will be listed here.

Abstract

The status of axillary lymph nodes is an important prognostic factor in the outcome of breast cancer tumors. New trials changed the attitude towards axillary clearance. In the era of development of new immune therapies for breast cancer, it is important to identify a biomarker that can predict lymph node status. Tumor-infiltrating lymphocytes (TILs) are a valuable indicator of the immune microenvironment that plays the central role in new anticancer drugs. Although the correlation between TILs and response to chemotherapy was established by previous studies, our retrospective study investigated the correlation between TILs and lymph node status. We analyzed data on 172 patients. According to stage, patients were divided in two groups: patients who underwent primary surgical treatment (breast-conserving or mastectomy and sentinel lymph node (SLN) biopsy +/- axillary clearance in conformity with lymph node status) and patients who received chemotherapy prior to surgical treatment (breast-conserving or mastectomy + axillary clearance). We showed a good inverse correlation between TILs and lymph nodes status for both early stage and locally advanced breast cancers. Moreover, TILs are a predictor for positive lymph nodes in the axilla in patients undergoing axillary clearance after SLN biopsy, with no statistical difference between the intrinsic or histological subtype of breast cancers. We also obtained a significant correlation between TILs and response to chemotherapy with no significative difference according to histological subtype. Although further data have still to be gathered before meeting the criteria for clinical utility, this study demonstrates that TILs are one of the most accredited forthcoming biomarkers for breast cancer (BC) patients.

Citing Articles

Elevated expression of ELK1 promotes breast cancer cell growth and correlates with poor prognosis of breast cancer patients.

Xu X, Wang Y, Wang Q, Lv S, Mao G Ann Med Surg (Lond). 2024; 86(10):5767-5775.

PMID: 39359848 PMC: 11444635. DOI: 10.1097/MS9.0000000000002256.

The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.

Liu D, Heij L, Czigany Z, Dahl E, Lang S, Ulmer T J Exp Clin Cancer Res. 2022; 41(1):127.

PMID: 35392957 PMC: 8988317. DOI: 10.1186/s13046-022-02340-2.

Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer.

Takada K, Kashiwagi S, Asano Y, Goto W, Kouhashi R, Yabumoto A BMC Womens Health. 2021; 21(1):225.

PMID: 34051785 PMC: 8164786. DOI: 10.1186/s12905-021-01373-7.

The expression and prognostic value of the epidermal growth factor receptor family in glioma.

Xu B, Huo Z, Huang H, Ji W, Bian Z, Jiao J BMC Cancer. 2021; 21(1):451.

PMID: 33892666 PMC: 8063311. DOI: 10.1186/s12885-021-08150-7.

Prediction of lymph node metastasis by tumor-infiltrating lymphocytes in T1 breast cancer.

Takada K, Kashiwagi S, Asano Y, Goto W, Kouhashi R, Yabumoto A BMC Cancer. 2020; 20(1):598.

PMID: 32590956 PMC: 7318528. DOI: 10.1186/s12885-020-07101-y.

References

Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A . Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002; 347(16):1227-32. DOI: 10.1056/NEJMoa020989. View

Aaltomaa S, Lipponen P, Eskelinen M, Kosma V, Marin S, Alhava E . Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer. 1992; 28A(4-5):859-64. DOI: 10.1016/0959-8049(92)90134-n. View

Schoppmann S, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M . Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg. 2004; 240(2):306-12. PMC: 1356408. DOI: 10.1097/01.sla.0000133355.48672.22. View

Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V . Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 2006; 7(12):983-90. DOI: 10.1016/S1470-2045(06)70947-0. View

Giuliano A, Hunt K, Ballman K, Beitsch P, Whitworth P, Blumencranz P . Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011; 305(6):569-75. PMC: 5389857. DOI: 10.1001/jama.2011.90. View

Hanahan D, Coussens L . Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012; 21(3):309-22. DOI: 10.1016/j.ccr.2012.02.022. View

Azimi F, Scolyer R, Rumcheva P, Moncrieff M, Murali R, McCarthy S . Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012; 30(21):2678-83. DOI: 10.1200/JCO.2011.37.8539. View

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G . The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2014; 26(2):259-71. PMC: 6267863. DOI: 10.1093/annonc/mdu450. View

Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali H . Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015; 6(7):5449-64. PMC: 4467160. DOI: 10.18632/oncotarget.3216. View

10.

Ali H, Glont S, Blows F, Provenzano E, Dawson S, Liu B . PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol. 2015; 26(7):1488-93. DOI: 10.1093/annonc/mdv192. View

11.

Hatzis C, Fraser Symmans W, Zhang Y, Gould R, Moulder S, Hunt K . Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer. Clin Cancer Res. 2015; 22(1):26-33. DOI: 10.1158/1078-0432.CCR-14-3304. View

12.

Soysal S, Tzankov A, Muenst S . Role of the Tumor Microenvironment in Breast Cancer. Pathobiology. 2015; 82(3-4):142-52. DOI: 10.1159/000430499. View

13.

Park I, Kong S, Ro J, Kwon Y, Kang J, Mo H . Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. Clin Breast Cancer. 2015; 16(1):51-8. DOI: 10.1016/j.clbc.2015.07.006. View

14.

Manca G, Rubello D, Tardelli E, Giammarile F, Mazzarri S, Boni G . Sentinel Lymph Node Biopsy in Breast Cancer: Indications, Contraindications, and Controversies. Clin Nucl Med. 2015; 41(2):126-33. DOI: 10.1097/RLU.0000000000000985. View

15.

Ohtani H, Mori-Shiraishi K, Nakajima M, Ueki H . Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis. Pathol Int. 2015; 65(12):644-51. PMC: 4738403. DOI: 10.1111/pin.12355. View

16.

Baptista M, Sarian L, Derchain S, Pinto G, Vassallo J . Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol. 2015; 47(1):78-84. DOI: 10.1016/j.humpath.2015.09.006. View

17.

Stanton S, Adams S, Disis M . Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. JAMA Oncol. 2016; 2(10):1354-1360. DOI: 10.1001/jamaoncol.2016.1061. View

18.

Galluzzi L, Zitvogel L, Kroemer G . Immunological Mechanisms Underneath the Efficacy of Cancer Therapy. Cancer Immunol Res. 2016; 4(11):895-902. DOI: 10.1158/2326-6066.CIR-16-0197. View

19.

Fraser Symmans W, Wei C, Gould R, Yu X, Zhang Y, Liu M . Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol. 2017; 35(10):1049-1060. PMC: 5455352. DOI: 10.1200/JCO.2015.63.1010. View

20.

Zhang S, Zhang D, Gong M, Wen L, Liao C, Zou L . High lymphatic vessel density and presence of lymphovascular invasion both predict poor prognosis in breast cancer. BMC Cancer. 2017; 17(1):335. PMC: 5436442. DOI: 10.1186/s12885-017-3338-x. View